Systems and methods for reagentless test strips

Abstract

A system for detecting an analyte with a reagentless dry test strip includes a collector for collecting a blood sample from a user. The system additionally includes a mixer for receiving the collector and mixing the blood sample. The system additionally includes reagents, located in the mixer, for mixing with the blood sample. The system additionally includes a dry test strip for receiving the blood sample mixed with the reagents.

Claims

1. A system for detecting an analyte with a reagentless dry test strip, comprising: a dry test strip including a reagentless membrane which does not include any reagents; a collector for collecting a blood sample from a user; a mixer separate from and shaped to mate with the collector, the mixer having a first condition separate from the collector and a second condition mated with the collector; and one or more reagents in the liquid form located in the mixer for forming a mixture with the blood sample when the mixer is mated with the collector, the one or more reagents effective to cause a color change of the mixture while within the mixer prior to dosing the mixture to the dry test strip, the reagentless membrane of the dry test strip being configured for receiving the mixture from the mixer.

2. The system of claim 1, wherein the collector includes a capillary tube.

3. The system of claim 1, wherein the mixer is shaped to seal with the collector when the collector is inserted into the mixer.

4. The system of claim 1, wherein the dry test strip includes a spreading layer.

5. The system of claim 1, wherein the dry test strip includes a first red blood cell separation layer.

6. The system, of claim 5, wherein the dry test strip includes a second red blood cell separation layer.

7. The system of claim 1, wherein the one or more reagents provide for the testing of total cholesterol.

8. The system of claim 7, wherein the one or more reagents include cholesterol esterase, cholesterol oxidase, horseradish peroxidase, and quinoneimine chromophore precursors selected from the list consisting of: 4-amino antipyrine (4-AAP) and N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline, sodium salt and monohydrate (MAOS).

9. The system of claim 1 and further comprising: a casing receiving the dry test strip and defining an application window; and a first red blood cell separation layer received in the casing and positioned closer to the application window than the reagentless membrane.

10. The system of claim 1 and further comprising: a casing receiving the dry test strip and defining a reading window, the reagentless membrane being positioned adjacent to the reading window; and a first red blood cell separation layer is received in the casing and positioned closer to the reading window than the reagentless membrane.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIGS. 1a and 1b show one embodiment of a sample collector with whole blood and the method for collecting capillary whole blood from a finger stick;

(2) FIG. 2 shows the sample collector of FIG. 1a inserted into one embodiment of the mixer containing reagents;

(3) FIG. 3 shows one embodiment of a test strip for use with a premix step;

(4) FIGS. 4-10 show graphs illustrating the dose response at increasing cholesterol concentrations tested in one embodiment of a reagentless test strip with a premixed solution applied; and

(5) FIGS. 11 and 12 shows kinetic curves for a 3.2 L effective sample size in a dry test strip compared to a strip where the reagents have been impregnated in the membrane.

DETAILED DESCRIPTION

(6) Certain terminology is used herein for convenience only and is not to be taken as a limitation on the embodiments of the systems and methods for reagentless test strips. In the drawings, the same reference letters are employed for designating the same elements throughout the several figures. Systems and methods for reagentless test strips include a premix step in a handheld mixer where reaction occurs prior to dosing on a reagentless dry test strip. Since the mixing in this process is more complete and less preservatives are required, the usage of available reagent is also more complete as compared to a dry test strip process.

(7) Dry test strip systems (including CardioChek test strips) typically use a dry test strip chemistry format, where the membranes are impregnated with expensive formulary. The main components in the formulary are the expensive enzymes which are added 10 to 30 times in excess to ensure there is sufficient active enzyme molecules (over the life of the lot) to confer reactivity to the substrate to yield a reaction and, thus, color development (often using the Trinder reaction). In addition, costly chromophores generating precursors, stabilizers, and dye mortants are added to maintain the stability and smooth color development of the test strip when dosed with a whole blood sample. A typical system includes a spreading layer, one or more layers for separating hematocrit and unselected analytes, and a reaction layer. The most costly elements of the test strip typically are found in the reaction layer and the separation layers.

(8) Systems and methods for reagentless test strips offer significant reduction in enzyme usage by not impregnating the reaction membrane, but using the dry test strip format to interrogate the color developed using the reflectance methodology. Advantages include: 1. Significantly less enzymes will be used per test, thus significantly reducing cost per test. 2. Reduction in strip-to-strip variation due to inconsistent impregnation methods on the membrane. 3. Will eliminate expensive in-process membrane checks to ensure if the impregnated membranes meet quality control criteria.

(9) The samples (capillary or venous whole blood) will be collected by a collector as shown in FIGS. 1a and 1b, and placed in a mixer as shown in FIG. 2. FIGS. 1a and 1b show one embodiment of a sample collector with whole blood and the method for collecting capillary whole blood from a finger stick. FIG. 2 shows the sample collector inserted into the mixer containing reagents. Alternatively, the sample collector may include a cap or other closure device for providing for a seal during mixing. In one alternative, the sample collector may include a lancet as well as a capillary tube. The mixer portion contains appropriate enzymes (e.g., for a total cholesterol assay, the enzyme train of cholesterol esterase, cholesterol oxidase, horseradish peroxidase, and quinoneimine chromphore precursors like 4-amino antipyrine (4-AAP) and N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline, sodium salt, and monohydrate (MAOS) in a proprietary formulary for a specific analyte). The whole blood or serum sample is mixed with the enzyme system in the liquid form for a specific time and then dosed on a test strip (for example, a CardioChek strip (single test strip)) and read on an optical analyzer (e.g., a CardioChek analyzer). Although a formulary for total cholesterol is provided, a variety of analytes may be tested according to this method, including, but not limited to, total cholesterol, LDL, HDL, glucose, and triglycerides, among others.

(10) Embodiments of the single strip will be constructed in such a way that they will contain certain elements that will have the ability to spread the whole blood using a spreading layer, a blood separation layer made of borosilicate glass fiber membrane impregnated with lectins and other RBC capturing agents, and a secondary blood separation later. FIG. 3 shows one embodiment of a test strip for use with a premix step. The test strip 300 includes a spreading layer 310, a first blood separation layer 320, a second blood separation layer 330, a reaction layer 340 that does not contain any reagents, and casing 350 with anchoring posts 355. This is just an exemplary embodiment of a test strip 300, and the test strip 300 in alternative embodiments may have merely a single membrane or layer. Alternatively, the test strip may be a single reaction layer with one or more RBC (red blood cell) separation layers. Alternatively, a spreading layer additionally may be included with any of the above configurations. In one configuration, spreading layer 310 is Petex, slit to 0.200.180 inches. In one configuration, the first blood separation layer 320 is Tuffglass slit to 0.200.180 inches. Optionally, this layer is impregnated with lectins and other RBC capturing agents. In one configuration, the second blood separation layer 330 is CytoSep 1660, slit to 0.200.180 inches. In another configuration, the reaction layer 340 is 0.45 A Biodyne Membrane, slit to 0.200.180 inches.

(11) In some configurations, the optical reader may be replaced with a handheld electronic device such as a cell phone, PDA, or tablet. In some configurations, a blank test strip module in a casing that eliminates outside light, except from a single light source from lighting the test strip, may be provided that fits over the camera of the handheld electronic device. Therefore, a standard module with spreading and RBC separation layers may be provided at little cost; then each module may be configured by providing the corresponding premix collector and mixer, the collector and mixer containing reagents for testing for the analyte of interest.

(12) Results of prototypes including a premix step and a reagentless strip are discussed below.

Example 1

(13) A total cholesterol (TC) formulary was prepared using Polymer Technology Systems, Inc., work instruction. To a 100 L TC reaction formulation was added serum at various TC concentrations (see Table 1) at various volumes (see Table 2). The solution was mixed via vortex. 12 L of the final solution then were dosed on the test strip. Tables 1 and 2 show the results from this example.

(14) TABLE-US-00001 TABLE 1 Serum Serum TC Concentrations Levels (mg/dL) 1 123 2 192 3 263 4 333 5 400

(15) TABLE-US-00002 TABLE 2 Volume of TC Volume of Total Volume dosed Effective Sample reagent Serum Volume on Strip Volume dosed (L) (L) (L) (L) (L) 100 20 120 12 1.85 100 25 125 12 2.30 100 30 130 12 2.77 100 35 135 12 3.23 100 50 150 12 4.61 100 75 175 12 6.92 100 100 200 12 9.23

(16) The graphs of FIGS. 4-10 show the dose response at increasing cholesterol concentrations when the effective samples size increases from 1.85 to 9.4 L. For each graph, a linear regression and a second order polynomial equation and line has been computed to determine the curve-fitting equation for the graph. Graphs of FIGS. 4-8 all show better correlation (R2) to a polynomial fit line than to a linear regression line. While Graphs 7 and 10 both show there is no difference between the first and second ordered curve, the correlation in graph 10 is much lower compared to the correlation in graph 7 (R2 of 0.92 vs. 0.97). This indicates that the effective volume condition of 3.4 L of sample is optimal to yield a linear dose response across the dynamic range of the assay.

(17) Kinetic Data

(18) The data in FIGS. 11 and 12 shows the kinetic curve for a 3.2 L effective sample size compared to a strip where the reagents have been impregnated in the membrane.

(19) While specific embodiments have been described in detail in the foregoing detailed description and illustrated in the accompanying drawings, it will be appreciated by those skilled in the art that various modifications and alternatives to those details could be developed in light of the overall teachings of the disclosure and the broad inventive concepts thereof. It is understood, therefore, that the scope of this disclosure is not limited to the particular examples and implementations disclosed herein but is intended to cover modifications within the spirit and scope thereof as defined by the appended claims and any and all equivalents thereof. Note that, although particular embodiments are shown, features of each may be interchanged between embodiments.